Cite
HARVARD Citation
Haddad, R. et al. (2022). Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal for immunotherapy of cancer. 10 (2), p. . [Online].